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Abstract
Many patients with cancer experience muscle wasting and weakness. Muscle wasting in 
patients with cancer can be caused by cachexia and sarcopenia. Both cachexia and sarco-
penia involve inflammation and oxidative stress. However, they differ in the underlying 
mechanisms that lead to muscle wasting. Cachexia involves the release of inflammatory 
cytokines due to cancer, while sarcopenia involves inflammation due to aging. Physical 
exercise has shown effectiveness for improving physical function, ability, and quality of 
life (QOL) in patients with cancer cachexia. On the other hand, no studies have investi-
gated the relationship between physical exercise and sarcopenia in elderly patients with 
cancer. Previous studies showed effectiveness for improving physical function in elderly 
patients with cancer. In the future, more studies are required on physical exercise in sar-
copenic elderly patients with cancer.
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1. Introduction
Muscle wasting and weakness are common in many disease states and conditions including 
aging and cancer [1]. Muscle wasting in advanced cancer is related to age, sex, tumor type, 
and inflammation [2]. It can be caused by inflammation and malnutrition in patients with 
cancer [3]. Patients with cancer have problems including anorexia, weight loss, negative nitro-
gen balance, and skeletal muscle wasting [4]. The loss of muscle and fat tissue due to chronic 
illness is referred to as cachexia, and the general loss of muscle mass with advancing age is 
referred to as sarcopenia [5]. Sarcopenia diagnosis requires documentation of low muscle 
mass along with either low muscle strength or low physical performance [6]. Cachexia and 
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sarcopenia share some pathological muscle wasting mechanisms characterized by inflamma-
tion and oxidative stress [7, 8]. In both cachexia and sarcopenia, muscle loss can lead to frailty 
and adversely affect various clinical outcomes [9]. Many oncologists and rehabilitation staffs 
confuse cancer cachexia with simple starvation or physiological processes such as sarcopenia. 
Since cancer cachexia and sarcopenia can both involve muscle wasting, we speculate that the 
two conditions can be confused in patients with cancer. However, sarcopenia and cachexia 
should not be confused in patients with cancer (Figure 1). Instead, it should be understood 
that the loss of skeletal muscle mass occurs in patients with cancer (cachexia) as well as dur-
ing aging (sarcopenia). Cachexia involves muscle wasting and weakness as a result of cancer-
related inflammation, while sarcopenia involves muscle wasting and weakness as a result 
of age-related inflammation. Thus, the underlying pathological processes leading to muscle 
wasting and weakness differ between the two conditions.
2. Cachexia
Cachexia is associated with cancer and other chronic diseases, and cachexia patients lose 
weight and experience a decline in their overall health. The mechanism of cancer cachexia 
is known to involve inflammatory cytokines such as tumor necrosis factor-alpha and inter-
leukin-6 [10]. Cancer cachexia is a complex syndrome that describes the progressive muscle 
wasting and weakness observed in many patients with cancer and accounts for at least 20% 
of cancer deaths [11, 12]. It is caused by numerous complex interactions of tumor and host 
factors [13, 14], and results in anorexia, wasting syndrome, and subsequent related issues [15]. 
Figure 1. Muscle wasting due to cancer cachexia and sarcopenia.
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It is a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass (with or 
without loss of fat mass) that cannot be fully reversed by conventional nutritional support 
[16]. A panel of experts has also defined consensus criteria for diagnosing cachexia in patients 
with cancer [16]: (1) weight loss > 5% over the past 6 months (in the absence of simple star-
vation); (2) BMI < 20 kg/m2 and any degree of weight loss > 2%; or (3) appendicular skeletal 
muscle index consistent with sarcopenia (males < 7.26 kg/m2; females < 5.45 kg/m2), and any 
degree of weight loss > 2%. A defining feature of cancer cachexia is the loss of muscle, but fat 
may also be lost [17]. Weight loss is involuntary, meaning that there is no desire or attempt to 
lose weight. Cancer cachexia usually worsens over time, and as weight loss increases, cancer 
cachexia patients also experience difficulties in daily activities.
Cancer cachexia has three clinical stages: precachexia, cachexia, and refractory cachexia [16]. 
The condition may occur in stages that are defined by differences in food intake, weight loss, 
and ability to function. In addition to muscle wasting and appetite loss, patients who have 
cancer anorexia–cachexia have a poor overall quality of life (QOL) and experience fatigue. 
They find it difficult to perform regular daily activities [18], and experience a significant 
symptom burden [19, 20]. Patients with cancer cachexia have significant decrease in physical 
function [21, 22], with low grip strength, and shorter walking distance even when controlling 
for muscle wasting [23, 24]. Also, cancer cachexia patients demonstrate lower physical activ-
ity [25–27]. In the early or mild stage, patients with cancer may only notice a slight loss of 
appetite. At the moderate stage, patients will notice more weight loss and often eat less than 
at the early and mild stages. In the severe stage, muscle wasting becomes markedly increased 
compared to the moderate stage, and the condition may be resistant to normal treatments 
such as dietary supplementation and nutritional support. Patients with cancer do not experi-
ence weight gain. Furthermore, patients may also have great difficulties in performing routine 
activities [16, 28]. Cachexia can reduce the physical activities of daily living (ADL) in patients 
with cancer [29]. Many patients with cancer cachexia experience decrease in physical function 
and ADL after muscle wasting. Thus, in addition to nutritional support, physical exercise may 
also contribute to improve the physical function in patients with cancer cachexia.
3. Sarcopenia
Sarcopenia, derived from a Greek word meaning “poverty of flesh,” is characterized by the 
triad of progressive loss of skeletal muscle mass, muscle strength, and physical performance 
[30]. It is defined as age-related muscle wasting; thus, sarcopenia frequently occurs in elderly 
people. European Working Group on Sarcopenia in Older People (EWGSOP) recommends 
that the diagnosis of sarcopenia in elderly patients should be based on the presence of both 
low muscle mass and low muscle function (strength or performance) [6]. EWGSOP uses 
these characteristics to further classify the condition into the stages of presarcopenia, sarco-
penia, and severe sarcopenia [6]. Sarcopenia has emerged as an important prognostic factor 
in elderly advanced patients with cancer [6]. Modalities used to assess sarcopenia include 
magnetic resonance imaging, computed tomography, dual-energy X-ray absorptiometry, and 
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bioelectrical impedance analysis [31]. Sarcopenia is associated with poor performance status, 
toxicity from chemotherapy, and short time of tumor control [32, 33].
Sarcopenia is now recognized as a multifactorial geriatric syndrome [34, 35], and is a com-
mon clinical symptom of elderly patients with cancer [36]. It has been reported to serve as an 
independent risk factor for poor prognosis indicative of disease and death [37]. It typically 
co-occurs with cachexia in patients with cancer [38]. However, changes in muscle mass and 
physical performance may occur before clinically overt cachexia in patients with cancer [35]. 
In recent years, clinical research on the application of exercise, nutritional support, and drugs, 
as well as other comprehensive interventions in sarcopenia patients have demonstrated good 
results [39]. A significant proportion of elderly patients with cancer are at risk of sarcopenia 
development. However, despite its potential impact on their quality of life [2, 40], limited data 
are available regarding the factors associated with sarcopenia in elderly patients with cancer, 
who might have more problems such as malnutrition than non sarcopenic patients.
4. Physical exercise
Physical exercise has the potential to help maintain or slow the loss of physical function [41] 
as well as sustain and build muscle mass [42]. Aerobic and resistance exercise have been 
found to better improve upper and lower body strength than usual care in patients with can-
cer [42]. Aerobic exercise training for skeletal muscles improves wasting in cardiac and cancer 
cachexia patients [43]. Resistance exercise attenuates muscle wasting associated with a variety 
of catabolic conditions [44]. Physical exercise has been shown to be effective in improving 
physical activity levels in cancer survivors [45]. Physical activity intervention significantly 
improved quality of life for cancer cachexia patients [46, 47]. A systematic review found that 
physical activity has benefits including improvement in physical activity levels, aerobic fit-
ness, muscle strength, functional quality of life, anxiety, and self-esteem [48] (Figure 2).
Physical activity correlated with maximum exercise capacity, weight loss, blood hemoglo-
bin concentration, C-reactive protein, and QOL-related factors of physical functioning and 
bodily pain in patients with cancer with progressive cachexia [49]. Physical exercise may pro-
mote a disruption in the cycle of events leading to cachexia advancement (i.e. muscle tissue 
loss via anorexigenic proinflammatory cytokines) and, in turn, enhanced functionality and 
thus, improved QOL in patients with cancer [50]. It has been suggested to counteract sus-
tained disease-related inflammation and the effect of exercise training in cancer cachexia [51]. 
Furthermore, it has been shown an association with the reduced levels of C-reactive protein 
in patients with cancer [52].
In patients with cancer, physical exercise represents a function-preserving,  anti-inflammatory, 
and metabolism-modulating strategy with a low cost [53]. It may reverse protein degradation 
while increasing protein synthesis and lean body mass, thus counteracting the wasting seen 
in cachexia [54]. It is necessary to develop a better understanding of how to support patients 
with cancer in starting and maintaining physical activity and exercise programs. It is uncer-
tain whether physical activity during and following cancer treatment has the same  benefits 
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in the weight-stable and weight-losing patients. The question also remains as to whether 
physical exercise has any health benefit in people with cancer cachexia or those at risk of 
cancer cachexia. Research investigating physical exercise in patients with cancer undergoing 
treatment has demonstrated improvements in physical performance, fatigue, and functional 
quality of life. It is unclear whether these benefits are experienced by patients with cancer 
cachexia. There is insufficient evidence to establish the safety and effectiveness of physical 
exercise in cancer cachexia patients, and future trials on exercise and supportive care inter-
ventions are required in this population. Aerobic and resistance exercise regimens may have 
positive effects on decreasing cancer-related fatigue and muscle wasting in patients with can-
cer cachexia.
To date, no studies have shown a relationship between physical exercise and cancer sarcope-
nia. In elderly patients with cancer, physical exercise has several benefits including improv-
ing immune function [55], hemoglobin and red blood cell count [56], and physical activity 
[57], not but VO2peak, 1 repetition maximum, functional capacity, anxiety level, or emotional 
well-being [58]. Physical exercise seems to improve physical function and immune function 
in elderly patients with cancer [59]. However, it has not shown effectiveness for sarcopenic 
patients with cancer.
5. Summary and conclusion
Muscle wasting is often encountered in patients with cancer. Both cachexia and sarcopenia 
lead to muscle wasting in patients with cancer. However, the different mechanisms of muscle 
wasting in patients with cancer should be recognized. Physical exercise might be effective 
for improving physical function, physical activity, ADL, and QOL in patients with cancer 
cachexia. In the future, more studies are required on physical exercise in sarcopenic elderly 
Figure 2. The effectiveness of physical exercise for patients with cancer with cachexia and sarcopenia.
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patients with cancer. Studies investigating the combined effect of physical exercise and nutri-
tional therapies such as branched chain amino acids in cancer rehabilitation are required to 
improve patient outcomes in the future.
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